Frequency and outcomes of BRAF alterations identified by liquid biopsy in metastatic, non-colorectal gastrointestinal cancers
The Oncologist · 2025
DOI: 10.1093/oncolo/oyaf044 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Oncologist, 2025. Verfasst von Amit Mahipal und 5 weiteren Autor:innen. Beteiligte Einrichtung: University Hospitals Seidman Cancer Center, Case Western Reserve University, Cleveland, OH, United States. Hauptthemen laut MEDLINE: Proto-Oncogene Proteins B-raf, Gastrointestinal Neoplasms, Biomarkers, Tumor. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Impact of BRAF V600E mutations (BRAFV600E), a poor prognostic factor in metastatic colorectal cancer, is lacking in non-CRC gastrointestinal (GI) cancers including pancreatic (PDAC), gastric/gastroesophageal (GEA), hepatocellular carcinoma (HCC), and cholangiocarcinoma (CCA). Due to tumor-agnostic approvals for patients with BRAFV600E, understanding the frequency and impact of BRAF alterations across non-CRC GI cancers is essential for clinical decision-making.
Methods
Patients with PDAC, GEA, HCC, or CCA who had cell-free DNA detected on Guardant360 (Guardant Health) from 2020 to 2023 were queried. Prevalence of characterized BRAF genomic alterations (GA) was calculated; GAs were grouped by class (Class I/II/III). The Chi-squared test assessed differences between cancer types. A subset of patients had outcomes analysis using GuardantINFORM, a real-world clinicogenomic database, to derive real-world overall survival (rwOS).
Results
Of 32 480 included patients, BRAF GAs were identified in 4.4%; 19% were BRAFV600E (0.81% prevalence overall). CCA had the highest rate of BRAF GAs and BRAFV600E (P < .01); HCC and GEA had the highest rates of BRAF class II/III alterations. There were no significant differences in rwOS by alteration class or cancer type; numeric differences were observed by alteration class. Few patients were treated with BRAF inhibitors (2.2%). Prevalence of co-occurring alterations was unique by cancer type.
Conclusions
Frequency of BRAF GAs, including BRAFV600E, in non-CRC GI cancers detected by liquid biopsy is similar to tissue-based rates and can be reliably used to assess BRAF status. BRAF GAs have mixed prognostic implications on survival for patients with non-CRC GI malignancies that warrant further exploration.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- University Hospitals Seidman Cancer Center, Case Western Reserve University, Cleveland, OH, United States.
- Mayo Clinic, Rochester, MN, United States.
- Guardant Health Inc, Palo Alto, CA, United States.
ORCID-Profile: Amit Mahipal
Zitieren
APA
Mahipal, A., Bucheit, L., Zhang, N., Barnett, R. M., Storandt, M. H., & Chakrabarti, S. (2025). Frequency and outcomes of BRAF alterations identified by liquid biopsy in metastatic, non-colorectal gastrointestinal cancers. The Oncologist. https://doi.org/10.1093/oncolo/oyaf044
Vancouver
Mahipal A, Bucheit L, Zhang N, Barnett RM, Storandt MH, Chakrabarti S. Frequency and outcomes of BRAF alterations identified by liquid biopsy in metastatic, non-colorectal gastrointestinal cancers. The Oncologist. 2025. doi:10.1093/oncolo/oyaf044
BibTeX
@article{Mahipal2025,
author = {Mahipal, Amit and Bucheit, Leslie and Zhang, Nicole and Barnett, Reagan M and Storandt, Michael H and Chakrabarti, Sakti},
title = {Frequency and outcomes of BRAF alterations identified by liquid biopsy in metastatic, non-colorectal gastrointestinal cancers},
journal = {The Oncologist},
year = {2025},
doi = {10.1093/oncolo/oyaf044}
}
EUVIMED